Literature DB >> 29056986

Adjunctive Trazodone and Depression Outcome in Adolescents Treated with Serotonin Re-uptake Inhibitors.

Meshal A Sultan1, Darren B Courtney2,3.   

Abstract

OBJECTIVES: Recent published evidence suggests that adjunctive trazodone treatment may limit serotonin reuptake inhibitor (SRI) response in depressed adolescents in the context of a controlled trial. This study examined the effects of adjunctive trazodone on depression outcome in adolescents in a naturalistic treatment environment.
METHODS: We conducted a cohort study through chart review of a clinical sample. Patients in our sample were 15 to 18 years of age treated with either a selective serotonin reuptake inhibitor or serotonin and norepinephrine reuptake inhibitor. The treatment took place in the setting of a partial hospitalization program at a tertiary care centre from 2009-2014. The main outcome measure was the change in Beck Depression Inventory II (BDI-II) score from admission to discharge. We compared this outcome in patients who were exposed to adjunctive trazodone treatment compared to adolescents who did not receive trazodone in the final four weeks of the program.
RESULTS: Exposure to trazodone was significantly associated with non-response to treatment in our sample (n= 35; β1= -7.76; 95% CI -0.52 to - 15.0; p<0.05; R2 = 0.13). In exploring potential confounders, higher baseline BDI-II scores appeared to predict greater change in BDI-II scores from pre- to post-treatment.
CONCLUSION: In keeping with previous research, we found that trazodone exposure was associated with treatment non-response in adolescents taking SRIs. The findings should be interpreted cautiously since they are limited by small sample size. Future randomized controlled trials of trazodone in samples of adolescents taking SRIs for depression are warranted.

Entities:  

Keywords:  adolescent; depression; selective serotonin re-uptake inhibitor; trazodone; treatment-resistant depression

Year:  2017        PMID: 29056986      PMCID: PMC5642463     

Source DB:  PubMed          Journal:  J Can Acad Child Adolesc Psychiatry        ISSN: 1719-8429


  20 in total

1.  Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine.

Authors:  M Maes; H Westenberg; E Vandoolaeghe; P Demedts; A Wauters; H Neels; H Y Meltzer
Journal:  J Clin Psychopharmacol       Date:  1997-10       Impact factor: 3.153

2.  Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes.

Authors:  Graham J Emslie; Taryn Mayes; Giovanna Porta; Benedetto Vitiello; Greg Clarke; Karen Dineen Wagner; Joan Rosenbaum Asarnow; Anthony Spirito; Boris Birmaher; Neal Ryan; Betsy Kennard; Lynn DeBar; James McCracken; Michael Strober; Matthew Onorato; Jamie Zelazny; Marty Keller; Satish Iyengar; David Brent
Journal:  Am J Psychiatry       Date:  2010-05-17       Impact factor: 18.112

Review 3.  Role of 5-HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies.

Authors:  A M Gardier; I Malagié; A C Trillat; C Jacquot; F Artigas
Journal:  Fundam Clin Pharmacol       Date:  1996       Impact factor: 2.748

4.  Use of pharmacotherapy for insomnia in child psychiatry practice: A national survey.

Authors:  Judith A Owens; Carol L Rosen; Jodi A Mindell; Hal L Kirchner
Journal:  Sleep Med       Date:  2010-08       Impact factor: 3.492

Review 5.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.

Authors:  Sidney H Kennedy; Raymond W Lam; Roger S McIntyre; S Valérie Tourjman; Venkat Bhat; Pierre Blier; Mehrul Hasnain; Fabrice Jollant; Anthony J Levitt; Glenda M MacQueen; Shane J McInerney; Diane McIntosh; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Norma L Pearson; Arun V Ravindran; Rudolf Uher
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

Review 6.  A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence.

Authors:  P Blier; C de Montigny; Y Chaput
Journal:  J Clin Psychiatry       Date:  1990-04       Impact factor: 4.384

7.  Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study.

Authors:  Wael Shamseddeen; Gregory Clarke; Martin B Keller; Karen Dineen Wagner; Boris Birmaher; Graham J Emslie; Neal Ryan; Joan Rosenbaum Asarnow; Giovanna Porta; David A Brent
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-01-17       Impact factor: 2.576

8.  Insomnia moderates outcome of serotonin-selective reuptake inhibitor treatment in depressed youth.

Authors:  Graham J Emslie; Betsy D Kennard; Taryn L Mayes; Paul A Nakonezny; Lian Zhu; Rongrong Tao; Carroll Hughes; Paul Croarkin
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-01-18       Impact factor: 2.576

Review 9.  Treatment-resistant depression in adolescents: review and updates on clinical management.

Authors:  Fadi T Maalouf; Mia Atwi; David A Brent
Journal:  Depress Anxiety       Date:  2011-09-02       Impact factor: 6.505

10.  Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.

Authors:  David Brent; Graham Emslie; Greg Clarke; Karen Dineen Wagner; Joan Rosenbaum Asarnow; Marty Keller; Benedetto Vitiello; Louise Ritz; Satish Iyengar; Kaleab Abebe; Boris Birmaher; Neal Ryan; Betsy Kennard; Carroll Hughes; Lynn DeBar; James McCracken; Michael Strober; Robert Suddath; Anthony Spirito; Henrietta Leonard; Nadine Melhem; Giovanna Porta; Matthew Onorato; Jamie Zelazny
Journal:  JAMA       Date:  2008-02-27       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.